The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Fibrolamellar Research Funding
FCF aims to drive and support high-impact research that is critical for the discovery of better treatments for FLC. To that end, we offer funding opportunities to both academic and industry investigators intended to support the research priorities identified by our Medical & Scientific Advisory Board.
Currently active funding opportunities include our ongoing research grant program, as well as our newly adopted awards incentive program for making FLC cell lines and model systems available to the research community.
Applications are reviewed three times annually, with application deadlines of March 1, July 1 and November 1 each year. The Foundation is also open to time sensitive requests – particularly for truly innovative ideas – throughout the year, with agreement prior to submission.
Applicants must be employed by an institution engaged in health-related research. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals.
Collaboration and open sourcing are a requirement for FCF funding, as will be specified in any grant agreement. The Foundation believes that collaboration and engaging the best talent across institutions, together with early sharing of data and resources, can accelerate the path to a cure for rare cancers like FLC.